Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Cuprizone demyelination of the corpus callosum in mice correlates with altered social interaction and impaired bilateral sensorimotor coordination.
Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients.
Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity.
Time-dependent changes in the brain arachidonic acid cascade during cuprizone-induced demyelination and remyelination.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression.
Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication.
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Delayed visual evoked response in optic neuritis.
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
Masitinib mesylate application for conditional approval
Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.
Estrogen and testosterone therapies in multiple sclerosis.
Clinically isolated syndrome - Rethinking the diagnosis.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
BG 12: BG 00012, BG 12/Oral Fumarate, FAG-201, second-generation fumarate derivative--Fumapharm/Biogen Idec.
Direct immunomodulatory influence of IFN-β on human astrocytoma cells.
SJL mice exposed to cuprizone intoxication reveal strain and gender pattern differences in demyelination.
Neuroprotection in a novel mouse model of multiple sclerosis.
Interleukin-1beta promotes repair of the CNS.
No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort.
Sequential myelin protein expression during remyelination reveals fast and efficient repair after central nervous system demyelination.
Reduction of CD8+ T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
Pages
« first
‹ previous
…
18
19
20
21
22
23
24
25
26
…
next ›
last »